Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases
NANJING, CHINA, May 16, 2017 - (ACN Newswire) - A future where faecal transplants in China will cure conditions like autism, IBD, arthritis, Parkinson's disease and even MS was presented by global Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) in his keynote presentation on non Clostridium difficile conditions, to open the international China Microbiota Transplantation Conference in Nanjing (April 12-14, 2017).
| Prof. Thomas Borody, Founder and Medical Director, Centre for Digestive Diseases (CDD), Sydney, Australia |
| Prof. Borody (r) and China's FMT leader Professor Faming Zhang, Director, Intestinal Diseases Center, 2nd Affiliated Hospital, Nanjing Medical University |
Professor Borody, the Founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney, Australia said many diseases have a unique microbiome profile which can be progressively changed to a normal profile with FMT treatment. At the state-of-the-art CDD facility, Prof. Borody and his team have performed more than 12,000 FMTs.
Prof. Borody is at the forefront of FMT research, being the first to report successful treatment of IBD in 1988. He invented, among other therapies, the freeze-dried oral FMT capsule system. He is also recognized as the first physician to successfully formulate the highly effective Triple Therapy that would become the gold standard for treating Helicobacter pylori infection, which can lead to peptic ulcers and stomach cancer, so common in China.
In his keynote presentation, Prof. Borody also shared findings from recent ground-breaking clinical trials in IBD and autism, which he personally designed and remained involved in, as examples of the need for greater FMT clinical trial investment in serious diseases:
-- The FOCUS Study - the first adequately powered randomized double blind controlled trial for ulcerative colitis -- The Autism Study - where cognitive improvement change was found after just 5 weeks of treatment
He said more research funding was needed to bring FMT treatment into the mainstream medical world. "The healthy human flora or its components, appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonization of the damaged gut microbiome," said Prof. Borody.
Prior to the conference Prof. Borody visited the FMT Bank in Nanjing with China's FMT leader Professor Faming Zhang, who was the first to perform FMT in China and has carried out over 1600 treatments to date. Prof. Borody has collaborated closely with Professor Faming Zhang, who is the Director of Intestinal Diseases Center at the 2nd Affiliated Hospital, Nanjing Medical University.
Like the US and Australia, China is facing increasing challenges around the management of diseases, many with rising incidence including IBD, Parkinson's disease, MS, and many autoimmune conditions.
About: What is Faecal Microbiota Transplantation
The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria.
FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition.
The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions.
The Centre for Digestive Diseases offers FMT primarily for the treatment of Clostridium difficile and treats selected patients with ulcerative colitis, irritable bowel sydrome, constipation and Crohn's disease. Other conditions are assessed on a case by case basis.
About: Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist (www.cdd.com.au)
Prof. Thomas Borody is the founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments.
Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments.
Contact: Susan Fitzpatrick-Napier Digital Mantra Group Team@dmgpr.com SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238
Source: Centre for Digestive Diseases (CDD) Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
| New circuit challenge for TOYOTA GAZOO Racing Apr 15, 2024 17:21 JST
| TOYOTA GAZOO Racing back on asphalt for Croatian challenge Apr 12, 2024 19:36 JST
| Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project Apr 12, 2024 14:39 JST
| MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors Apr 11, 2024 18:08 JST
| Mitsubishi Shipbuilding Acquires Approval in Principle (AiP) from Classification Society ClassNK for Ammonia Fuel Supply System (AFSS) Apr 11, 2024 17:50 JST
| DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission Apr 11, 2024 15:10 JST
| Mitsubishi Corporation Announces Completion of Capital Raise by Nexamp Apr 11, 2024 13:07 JST
| Mitsubishi Shipbuilding Receives Order for Ammonia Fuel Supply System for Ammonia-Powered Marine Engine Apr 10, 2024 16:55 JST
| Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 Apr 10, 2024 13:36 JST
|
More Latest Release >>
|